KR910006326A - 칼슘 채널의 차단제로서 유용한 폴리펩티드 - Google Patents

칼슘 채널의 차단제로서 유용한 폴리펩티드 Download PDF

Info

Publication number
KR910006326A
KR910006326A KR1019900015349A KR900015349A KR910006326A KR 910006326 A KR910006326 A KR 910006326A KR 1019900015349 A KR1019900015349 A KR 1019900015349A KR 900015349 A KR900015349 A KR 900015349A KR 910006326 A KR910006326 A KR 910006326A
Authority
KR
South Korea
Prior art keywords
cys
gly
lys
ile
arg
Prior art date
Application number
KR1019900015349A
Other languages
English (en)
Other versions
KR930007435B1 (ko
Inventor
필립스 더글라스
에이. 사코마노 니콜라스
에이. 볼크만 로버트
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
헌터 잭슨
내츄랄 프로덕트 사이언시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드, 헌터 잭슨, 내츄랄 프로덕트 사이언시스, 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR910006326A publication Critical patent/KR910006326A/ko
Application granted granted Critical
Publication of KR930007435B1 publication Critical patent/KR930007435B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

칼슘 채널의 차단제로서 유용한 폴리펩티드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. (a)아겔레놈시스 아페르타(Agelenopsis aperta) 거미의 조 독을 C-18Vydac (22㎜×250㎜, 300A 기공 크기, 10μ입자크기)컬럼상에서, 15㎖/분의 유속 및 선형 구배 프로그램(5%→20% B, 95%→80% A [0→30분]후20%→70%B, 80%→30%A〔30→55분〕; 여기에서 A는 0.1% 수성 TFA 이고 B는 아세토니트릴이다)의 용매 시스템을 사용하여, 약 41.5분에 용출시켜 수득한 분획에 존재하고; (b) (a)의 분획을 C-18Vydac(10㎜×250㎜, 300A 기공크기, 5μ입자크기)컬럼상에서, 3.5㎖/분의 유속 및 이소크라틱 용매 시스템(70%A, 30%B; 여기에서 A는 0.1%수성 TFA이고 B는 아세토니트릴이다)을 사용하여, 약 7.5분에 용출시켜 수득한 분획에 존재하며; (c)하기 서열을 포함하는 아미노-말단 아미노산 서열: H2N-lys-lys-lys-cys-ile-ala-lys-asp-tyr-gly-arg-cys-lys-trp-gly-gly-thr-pro-cys-cys-arg-gly-arg-gly-cys-ile-cys-ser-ile-met-gly-thr-asn-cys-glu-cys-lys-pro-arg-leu-ile-met-glu-gly-leu- 을 특징으로 하는 실질적으로 순수한 폴리펩티드 또는 상기 폴리펩티드와 실질적으로 동일한 아미노산 서열 및 실질적으로 동일한 칼슘 채널 차단 활성을 갖는 폴리펩티드 및 이의 약제학적으로 허용되는 염.
  2. (a)아겔레놉시스 아페르타 거미의 조 독을C-18Vydac(22㎜×250㎜, 300A 기공크기, 10μ입자크기) 컬럼상에서, 15㎖/분의 유속 및 선형 구배 프로그램(5%→ 20%B, 95%→80%A [0 → 30분]후 20% → 70%B, 80% → 30%A 〔30→ 55분〕; 여기에서 A는 0.1%수성 TFA 이고 B는 아세토니트릴이다)의 용매 시스템을 사용하여, 약 41.5분에 용출시켜 수득한 분획에 존재하고; (b) (a)의 분획을 C-18 Vydac(22㎜×250㎜, 300Å기공크기, 5μ입자크기)컬럼상에서, 3.5㎖/분의 유속 및 이소크라틱 용매 시스템(70%A, 30%B; 여기에서 A는 0.1% 수성 TFA이고 B는 아세토니트릴이다)을 사용하여, 약7.5분에 용출시켜 수득한 분획에 존재하며;(c)하기 서열을 포함하는 아미노-말단 아미노산 서열: H2N-lys-lys-lys-cys-ile-ala-lys-asp-tyr-gly-arg-cys-lys-trp-gly-gly-thr-pro-cys-cys-arg-gly-arg-gly-cys-ile-cys-ser-ile-met-gly-thr-asn-cys-glu-cys-lys-pro-arg-leu-ile-met-glu-gly-leu-을 특징으로 하는 폴리펩티드 또는 이의 약제학적으로 허용되는 염.
  3. 제1항에 따르는 폴리펩티드 또는 이의 약제학적으로-허용되는 염의 칼슘 채널을 차단하는 양을 세포에 투여함을 특징으로 하는 세포내 칼슘 채널 차단 방법.
  4. 제3항에 있어서, 세포가 포유동물의 신경 및/또는 근육계인 방법.
  5. 제3항에 있어서, 세포가 무척추 동물의 신경 및/또는 근육계인 방법.
  6. 제2항에 따르는 폴리펩티드 또는 이의 약제학적으로-허용되는 염의 칼슘 채널을 차단하는 양을 세포에 투여함을 특징으로 하는 세포내 칼슘 차단 방법.
  7. 제6항에 있어서, 세포가 포유동물의 신경 및/또는 근육계인 방법.
  8. 제6항에 있어서, 세포가 무척추 동물의 신경 및/또는 근육계인 방법.
  9. 제1항에 따르는 폴리펩티드 또는 이의 약제학적으로-허용되는 염의 칼슘 채널을 차단하는 양 및 약제학적으로-허용되는 희석제 또는 담체를 함유하는 포유동물의 세포내 칼슘 채널을 차단하는 약제학적 조성물.
  10. 제2항에 따르는 폴리펩티드 또는 이의 약제학적으로-허용되는 염의 칼슘 채널을 차단하는 양 및 약제학적으로-허용되는 희석제 또는 담체를 함유하는 포유동물의 세포내 칼슘 채널을 차단하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900015349A 1989-09-29 1990-09-27 포유동물 및 무척추동물의 세포에서 칼슘 채널의 차단제로서 유용한 폴리펩티드 및 약제학적으로 허용되는 이의 염 KR930007435B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/415,139 US5122596A (en) 1989-09-29 1989-09-29 Polypeptides useful as blockers of calcium channels
US415139 1989-09-29
US415,139 1989-09-29

Publications (2)

Publication Number Publication Date
KR910006326A true KR910006326A (ko) 1991-04-29
KR930007435B1 KR930007435B1 (ko) 1993-08-10

Family

ID=23644517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900015349A KR930007435B1 (ko) 1989-09-29 1990-09-27 포유동물 및 무척추동물의 세포에서 칼슘 채널의 차단제로서 유용한 폴리펩티드 및 약제학적으로 허용되는 이의 염

Country Status (27)

Country Link
US (1) US5122596A (ko)
EP (1) EP0425096B1 (ko)
JP (1) JPH0692440B2 (ko)
KR (1) KR930007435B1 (ko)
CN (1) CN1033976C (ko)
AT (1) ATE103611T1 (ko)
AU (1) AU626203B2 (ko)
CA (1) CA2026418C (ko)
CZ (1) CZ283651B6 (ko)
DD (1) DD297652A5 (ko)
DE (1) DE69007739T2 (ko)
DK (1) DK0425096T3 (ko)
EG (1) EG19316A (ko)
ES (1) ES2053118T3 (ko)
FI (1) FI96865C (ko)
HU (1) HU208705B (ko)
IE (1) IE64218B1 (ko)
IL (1) IL95765A (ko)
MY (1) MY106832A (ko)
NO (1) NO175208C (ko)
NZ (1) NZ235496A (ko)
PH (1) PH27403A (ko)
PL (1) PL164541B1 (ko)
PT (1) PT95424B (ko)
RU (1) RU2026866C1 (ko)
YU (1) YU184490A (ko)
ZA (1) ZA907782B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5677288A (en) * 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
US5763568A (en) * 1992-01-31 1998-06-09 Zeneca Limited Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders
GB9208110D0 (en) * 1992-04-13 1992-05-27 Isis Innovation Assay for antibodies that bind calcium channels
JP2571197B2 (ja) * 1992-07-27 1997-01-16 ファイザー インク． アゲレノプシス・アペルタ由来のカルシウムチャンネル阻害ポリペプチド
WO1994015960A1 (en) * 1993-01-07 1994-07-21 Eisai Co., Ltd. Peptide with glutamate liberation inhibitor and calcium channel inhibitor activities
ES2075796B1 (es) * 1993-08-17 1996-03-01 Pfizer Polipeptido de la agelenopsis aperta bloqueante de los canales de ca lcio
JP2792518B2 (ja) * 1994-01-19 1998-09-03 ファイザー・インコーポレーテッド ゲオリコサ・リオグランデからの孔形成ペプチド
US5512592A (en) * 1994-09-09 1996-04-30 Wake Forest University Method of producing cardiotonic effect and improving cardiac contractile function by administration of carnosine
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US5756663A (en) * 1996-01-03 1998-05-26 Zeneca Limited Antiarrhythmic peptide from venom of spider Grammostola spatulata
WO1998036743A1 (en) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
JP2006056805A (ja) * 2004-08-18 2006-03-02 Senmi Ekisu Co Ltd カルシウムチャンネル阻害剤
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US4950739A (en) * 1988-02-10 1990-08-21 New York University Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels
IL92819A0 (en) * 1988-12-23 1990-09-17 Merrell Dow Pharma Polypeptides isolated from the venom of the spider hololena curta
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele

Also Published As

Publication number Publication date
NO904251L (no) 1991-04-02
DE69007739D1 (de) 1994-05-05
EP0425096B1 (en) 1994-03-30
DK0425096T3 (da) 1994-05-02
MY106832A (en) 1995-07-31
HUT55036A (en) 1991-04-29
NZ235496A (en) 1991-12-23
KR930007435B1 (ko) 1993-08-10
ZA907782B (en) 1992-05-27
IL95765A0 (en) 1991-06-30
YU184490A (sh) 1993-05-28
US5122596A (en) 1992-06-16
FI96865B (fi) 1996-05-31
ES2053118T3 (es) 1994-07-16
CA2026418A1 (en) 1991-03-30
CN1033976C (zh) 1997-02-05
JPH03120299A (ja) 1991-05-22
JPH0692440B2 (ja) 1994-11-16
PL164541B1 (pl) 1994-08-31
PT95424B (pt) 1998-06-30
NO904251D0 (no) 1990-09-28
FI904789A0 (fi) 1990-09-28
HU906267D0 (en) 1991-03-28
DE69007739T2 (de) 1994-07-07
CN1051182A (zh) 1991-05-08
AU626203B2 (en) 1992-07-23
PL287113A1 (en) 1991-09-09
RU2026866C1 (ru) 1995-01-20
HU208705B (en) 1993-12-28
FI96865C (fi) 1996-09-10
PH27403A (en) 1993-06-21
CA2026418C (en) 1996-09-24
CZ470790A3 (cs) 1998-02-18
AU6366090A (en) 1991-04-11
CZ283651B6 (cs) 1998-05-13
NO175208B (ko) 1994-06-06
IE64218B1 (en) 1995-07-26
EP0425096A1 (en) 1991-05-02
IL95765A (en) 1995-07-31
PT95424A (pt) 1991-05-22
EG19316A (en) 1994-12-30
DD297652A5 (de) 1992-01-16
NO175208C (no) 1994-09-14
IE903491A1 (en) 1991-04-10
ATE103611T1 (de) 1994-04-15

Similar Documents

Publication Publication Date Title
KR910006326A (ko) 칼슘 채널의 차단제로서 유용한 폴리펩티드
EP0515228B1 (en) Essentially pure human parathyroid hormone
DE69519454T2 (de) Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
DE69125035T2 (de) Verfahren zur herstellung von interferon-alpha-2 kristallen
DE69125764T2 (de) Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit
EP0209061A2 (de) Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
NO931141L (no) Tnf-muteiner
IT1219874B (it) Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
DE3712985A1 (de) Bifunktionelle proteine
KR950702577A (ko) 아젤레높시스 아페르타(agelenopsis aperta)로 부터의 칼슘 채널 차단 폴리펩티드(calcium channel blocking polypeptide from agelenopsis aperta)
FR2648048B1 (fr) Procede de preparation de solutions d'albumine purifiee
KR900009695A (ko) 홀로레나 커타종 거미독에서 분리한 폴리펩타이드
DE117470T1 (de) Verfahren zur herstellung von interferon (ifn-gamma) des typs 26k und 21k.
DE69312320T2 (de) Den kalzium kanal blokierende polypeptide aus filistata hibernalis.
EP1062237A1 (de) Metallhaltige ribonukleotidpolypeptide
ATE88188T1 (de) Verfahren zur herstellung von antihaemophilem faktor (faktor viii), der eine hohe reinheit aufweist.
DE69031596T2 (de) Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins
DE69318567T2 (de) Kalzium-kanal-blockierende polypeptide aus theraphosidae aphonopelma
ATE140928T1 (de) Proteine, die die expression von vertebraten-mhc- klasse-ii-genen regulieren, dafür kodierende dna- sequenzen und pharmazeutische zusammensetzungen
JP2792518B2 (ja) ゲオリコサ・リオグランデからの孔形成ペプチド
KR950003312A (ko) 연골세포 단백질
DE3906871C2 (ko)
AU643773B2 (en) Growth hormone releasing factor analogs
IE83494B1 (en) Essentially pure human parathyroid hormone
DE3908802A1 (de) Expressionsvektor, eukaryontische zellen und verfahren zur gewinnung von pdgf-aa

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080704

Year of fee payment: 16

LAPS Lapse due to unpaid annual fee